vs
Side-by-side financial comparison of Fidelity National Financial, Inc. (FNF) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.
Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $544.0M, roughly 1.1× Fidelity National Financial, Inc.). Royalty Pharma plc runs the higher net margin — 34.4% vs -21.5%, a 55.9% gap on every dollar of revenue. On growth, Fidelity National Financial, Inc. posted the faster year-over-year revenue change (10.3% vs 4.8%). Over the past eight quarters, Fidelity National Financial, Inc.'s revenue compounded faster (13.7% CAGR vs 4.6%).
Fidelity National Financial, Inc., is an American provider of title insurance and settlement services to the real estate and mortgage industries. A Fortune 500 company, Fidelity National Financial generated approximately $8.469 billion in annual revenue in 2019 from its title and real estate-related operations. The company was the first instance of an attorney licensed by a Native American Tribe being certified as "authorized house counsel" in the state of Florida.
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
FNF vs RPRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $544.0M | $622.0M |
| Net Profit | $-117.0M | $214.2M |
| Gross Margin | — | — |
| Operating Margin | 82.9% | 62.4% |
| Net Margin | -21.5% | 34.4% |
| Revenue YoY | 10.3% | 4.8% |
| Net Profit YoY | -126.0% | 2.9% |
| EPS (diluted) | $-0.44 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $544.0M | $622.0M | ||
| Q3 25 | $553.0M | $609.3M | ||
| Q2 25 | $547.0M | $578.7M | ||
| Q1 25 | $455.0M | $568.2M | ||
| Q4 24 | $493.0M | $593.6M | ||
| Q3 24 | $506.0M | $564.7M | ||
| Q2 24 | $504.0M | $537.3M | ||
| Q1 24 | $421.0M | $568.0M |
| Q4 25 | $-117.0M | $214.2M | ||
| Q3 25 | $358.0M | $288.2M | ||
| Q2 25 | $278.0M | $30.2M | ||
| Q1 25 | $83.0M | $238.3M | ||
| Q4 24 | $450.0M | $208.2M | ||
| Q3 24 | $266.0M | $544.0M | ||
| Q2 24 | $306.0M | $102.0M | ||
| Q1 24 | $248.0M | $4.8M |
| Q4 25 | 82.9% | 62.4% | ||
| Q3 25 | 81.9% | 70.1% | ||
| Q2 25 | 69.8% | 36.3% | ||
| Q1 25 | 24.4% | 94.0% | ||
| Q4 24 | — | 60.9% | ||
| Q3 24 | 61.9% | — | ||
| Q2 24 | 90.9% | 50.2% | ||
| Q1 24 | 78.6% | -13.0% |
| Q4 25 | -21.5% | 34.4% | ||
| Q3 25 | 64.7% | 47.3% | ||
| Q2 25 | 50.8% | 5.2% | ||
| Q1 25 | 18.2% | 41.9% | ||
| Q4 24 | 91.3% | 35.1% | ||
| Q3 24 | 52.6% | 96.3% | ||
| Q2 24 | 60.7% | 19.0% | ||
| Q1 24 | 58.9% | 0.8% |
| Q4 25 | $-0.44 | $0.49 | ||
| Q3 25 | $1.33 | $0.67 | ||
| Q2 25 | $1.02 | $0.07 | ||
| Q1 25 | $0.30 | $0.55 | ||
| Q4 24 | $1.65 | $0.46 | ||
| Q3 24 | $0.97 | $1.21 | ||
| Q2 24 | $1.12 | $0.23 | ||
| Q1 24 | $0.91 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.6B | $618.7M |
| Total DebtLower is stronger | $4.4B | $9.0B |
| Stockholders' EquityBook value | $7.4B | $9.7B |
| Total Assets | $109.0B | $19.6B |
| Debt / EquityLower = less leverage | 0.59× | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.6B | $618.7M | ||
| Q3 25 | $3.5B | $938.9M | ||
| Q2 25 | $3.3B | $631.9M | ||
| Q1 25 | $4.5B | $1.1B | ||
| Q4 24 | $3.5B | $929.0M | ||
| Q3 24 | $5.0B | $950.1M | ||
| Q2 24 | $4.9B | $1.8B | ||
| Q1 24 | $3.5B | $843.0M |
| Q4 25 | $4.4B | $9.0B | ||
| Q3 25 | $4.4B | $8.9B | ||
| Q2 25 | $4.4B | $8.0B | ||
| Q1 25 | $4.4B | $7.6B | ||
| Q4 24 | $4.3B | $7.6B | ||
| Q3 24 | $4.2B | $7.6B | ||
| Q2 24 | $4.2B | $7.6B | ||
| Q1 24 | $3.9B | $6.1B |
| Q4 25 | $7.4B | $9.7B | ||
| Q3 25 | $8.4B | $9.6B | ||
| Q2 25 | $7.9B | $9.5B | ||
| Q1 25 | $7.9B | $9.8B | ||
| Q4 24 | $7.8B | $10.3B | ||
| Q3 24 | $8.1B | $10.3B | ||
| Q2 24 | $7.3B | $9.8B | ||
| Q1 24 | $7.1B | $9.9B |
| Q4 25 | $109.0B | $19.6B | ||
| Q3 25 | $106.6B | $19.3B | ||
| Q2 25 | $102.3B | $18.3B | ||
| Q1 25 | $98.2B | $17.6B | ||
| Q4 24 | $95.4B | $18.2B | ||
| Q3 24 | $94.7B | $18.0B | ||
| Q2 24 | $88.8B | $17.7B | ||
| Q1 24 | $84.5B | $16.1B |
| Q4 25 | 0.59× | 0.92× | ||
| Q3 25 | 0.53× | 0.93× | ||
| Q2 25 | 0.56× | 0.84× | ||
| Q1 25 | 0.56× | 0.78× | ||
| Q4 24 | 0.56× | 0.74× | ||
| Q3 24 | 0.52× | 0.74× | ||
| Q2 24 | 0.58× | 0.78× | ||
| Q1 24 | 0.55× | 0.62× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.5B | $827.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 3.86× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.5B | $827.1M | ||
| Q3 25 | $1.3B | $702.6M | ||
| Q2 25 | $1.9B | $364.0M | ||
| Q1 25 | $1.1B | $596.1M | ||
| Q4 24 | $1.5B | $742.5M | ||
| Q3 24 | $2.4B | $703.6M | ||
| Q2 24 | $1.4B | $658.2M | ||
| Q1 24 | $1.6B | $664.6M |
| Q4 25 | — | 3.86× | ||
| Q3 25 | 3.66× | 2.44× | ||
| Q2 25 | 6.82× | 12.06× | ||
| Q1 25 | 13.43× | 2.50× | ||
| Q4 24 | 3.32× | 3.57× | ||
| Q3 24 | 8.89× | 1.29× | ||
| Q2 24 | 4.45× | 6.45× | ||
| Q1 24 | 6.42× | 139.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FNF
| Escrow Fees | $241.0M | 44% |
| Other Title Related Fees And Income | $182.0M | 33% |
| Service Link Excluding Title Premiums Escrow Fees And Subservicing Fees | $87.0M | 16% |
| Insurance Contracts Home Warranty | $31.0M | 6% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
